6-(2-aminoethylsulfonyl)-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-2-(2H-tetrazol-5-yl)benzenesulfonamide
C16H15N7O6S2 — CID 135150221
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-(2-aminoethylsulfonyl)-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-2-(2H-tetrazol-5-yl)benzenesulfonamide
6-(2-aminoethylsulfonyl)-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-2-(2H-tetrazol-5-yl)benzenesulfonamide (PubChem CID 135150221) has the molecular formula C16H15N7O6S2 and a molecular weight of 465.47 g/mol. Its IUPAC name is 6-(2-aminoethylsulfonyl)-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-2-(2H-tetrazol-5-yl)benzenesulfonamide.
Molecular Properties
| Compound Name | 6-(2-aminoethylsulfonyl)-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-2-(2H-tetrazol-5-yl)benzenesulfonamide |
|---|---|
| PubChem CID | 135150221 |
| Molecular Formula | C16H15N7O6S2 |
| Molecular Weight | 465.47 g/mol |
| Exact Mass | 465.05 |
| IUPAC Name | 6-(2-aminoethylsulfonyl)-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-2-(2H-tetrazol-5-yl)benzenesulfonamide |
| SMILES | NCCS(=O)(=O)c1ccc(-c2ccc3[nH]c(=O)oc3c2)c(-c2nn[nH]n2)c1S(N)(=O)=O |
| InChI | InChI=1S/C16H15N7O6S2/c17-5-6-30(25,26)12-4-2-9(8-1-3-10-11(7-8)29-16(24)19-10)13(14(12)31(18,27)28)15-20-22-23-21-15/h1-4,7H,5-6,17H2,(H,19,24)(H2,18,27,28)(H,20,21,22,23) |
| InChIKey | MTRXZAYDTGTVKL-UHFFFAOYSA-N |
| XLogP | -0.65 |
| TPSA | 220.78 Ų |
| H-Bond Donors | 4 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 465.47 |
| LogP ≤ 5 | -0.65 |
| H-Bond Donors ≤ 5 | 4 |
| H-Bond Acceptors ≤ 10 | 10 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135150221 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.